FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079118742> ?p ?o ?g. }

• W2079118742 abstract "Background: Trastuzumab-or lapatinib-based therapies are recommended by the National Comprehensive Cancer Network (NCCN) guidelines as preferred agents for metastatic HER2-positive breast cancer. Few studies have compared treatment patterns, healthcare resource utilization (HRU), and costs in metastatic breast cancer (MBC) patients receiving trastuzumab vs. lapatinib. The objective of this study was to compare discontinuation rates, HRU, and costs in MBC patients (pts) initiated on trastuzumab vs. lapatinib. Methods: MBC adult women initiated on trastuzumab or lapatinib on/after 03/13/2007 (lapatinib FDA-approval date) were selected from the US-based PharMetrics® Integrated Database (2000–2011). Selected pts were required to be continuously eligible in their healthcare plan ≥6 months prior to and ≥30 days following trastuzumab or lapatinib initiation date. Pts were observed over the period spanning from trastuzumab or lapatinib initiation date (without restriction on line of therapy) up to the end of continuous health plan enrollment or data availability, whichever occurred first. Trastuzumab or lapatinib discontinuation rates (gap ≥45 consecutive days) were compared using multivariate Cox proportional-hazards models and reported as hazard ratios (HRs). Incremental HRU was estimated using negative binomial regression models and reported as incidence rate ratios (IRRs). Monthly cost difference (2010 USD; measured from a payer perspective) were estimated using multivariate generalized linear or two-part models. Since a large proportion of lapatinib users were previously treated with trastuzumab, a sensitivity analysis was conducted to control for the impact of prior trastuzumab use. Results: Among the 643 pts selected, 381 and 262 pts were initiated on trastuzumab and lapatinib, respectively. Of the 262 pts initiated on lapatinib, 171 (65%) were previously treated with trastuzumab. After adjustment for confounders (demographics, index year, prior MBC therapies, comorbidities, baseline HRU, and MBC duration), compared to trastuzumab users, lapatinib users had a higher rate of treatment discontinuation (HR = 1.57; p Sensitivity analyses showed that pts who were initiated on lapatinib without prior trastuzumab use had a higher incidence of inpatient admissions (IRR = 1.74; p = .002) and greater overall medical service costs compared to pts who were initiated on trastuzumab (adjusted difference=$3,059; p Conclusion: Overall, while MBC pts initiated on trastuzumab or lapatinib had similar healthcare costs, pts initiated on lapatinib had higher rates of treatment discontinuation and outpatient visits (not treatment administration related). Medical costs were significantly higher among pts initiated on lapatinib without prior trastuzumab use. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-12." @default.
• W2079118742 created "2016-06-24" @default.
• W2079118742 creator A5019132733 @default.
• W2079118742 creator A5031808786 @default.
• W2079118742 creator A5039045250 @default.
• W2079118742 creator A5041026389 @default.
• W2079118742 creator A5047960113 @default.
• W2079118742 creator A5072015843 @default.
• W2079118742 creator A5085780425 @default.
• W2079118742 date "2012-12-15" @default.
• W2079118742 modified "2023-09-27" @default.
• W2079118742 title "Abstract P5-18-12: Comparison of treatment patterns and outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; a retrospective analysis" @default.
• W2079118742 doi "https://doi.org/10.1158/0008-5472.sabcs12-p5-18-12" @default.
• W2079118742 hasPublicationYear "2012" @default.
• W2079118742 type Work @default.
• W2079118742 sameAs 2079118742 @default.
• W2079118742 citedByCount "0" @default.
• W2079118742 crossrefType "proceedings-article" @default.
• W2079118742 hasAuthorship W2079118742A5019132733 @default.
• W2079118742 hasAuthorship W2079118742A5031808786 @default.
• W2079118742 hasAuthorship W2079118742A5039045250 @default.
• W2079118742 hasAuthorship W2079118742A5041026389 @default.
• W2079118742 hasAuthorship W2079118742A5047960113 @default.
• W2079118742 hasAuthorship W2079118742A5072015843 @default.
• W2079118742 hasAuthorship W2079118742A5085780425 @default.
• W2079118742 hasConcept C121608353 @default.
• W2079118742 hasConcept C126322002 @default.
• W2079118742 hasConcept C143998085 @default.
• W2079118742 hasConcept C207103383 @default.
• W2079118742 hasConcept C2775930923 @default.
• W2079118742 hasConcept C2777329042 @default.
• W2079118742 hasConcept C2778715236 @default.
• W2079118742 hasConcept C2779786085 @default.
• W2079118742 hasConcept C44249647 @default.
• W2079118742 hasConcept C50382708 @default.
• W2079118742 hasConcept C530470458 @default.
• W2079118742 hasConcept C71924100 @default.
• W2079118742 hasConceptScore W2079118742C121608353 @default.
• W2079118742 hasConceptScore W2079118742C126322002 @default.
• W2079118742 hasConceptScore W2079118742C143998085 @default.
• W2079118742 hasConceptScore W2079118742C207103383 @default.
• W2079118742 hasConceptScore W2079118742C2775930923 @default.
• W2079118742 hasConceptScore W2079118742C2777329042 @default.
• W2079118742 hasConceptScore W2079118742C2778715236 @default.
• W2079118742 hasConceptScore W2079118742C2779786085 @default.
• W2079118742 hasConceptScore W2079118742C44249647 @default.
• W2079118742 hasConceptScore W2079118742C50382708 @default.
• W2079118742 hasConceptScore W2079118742C530470458 @default.
• W2079118742 hasConceptScore W2079118742C71924100 @default.
• W2079118742 hasLocation W20791187421 @default.
• W2079118742 hasOpenAccess W2079118742 @default.
• W2079118742 hasPrimaryLocation W20791187421 @default.
• W2079118742 hasRelatedWork W2023063845 @default.
• W2079118742 hasRelatedWork W2034398512 @default.
• W2079118742 hasRelatedWork W2040300101 @default.
• W2079118742 hasRelatedWork W2075177845 @default.
• W2079118742 hasRelatedWork W2096365365 @default.
• W2079118742 hasRelatedWork W2112335800 @default.
• W2079118742 hasRelatedWork W2137771360 @default.
• W2079118742 hasRelatedWork W2402241632 @default.
• W2079118742 hasRelatedWork W2606091139 @default.
• W2079118742 hasRelatedWork W2606703501 @default.
• W2079118742 hasRelatedWork W2768165937 @default.
• W2079118742 hasRelatedWork W2886334050 @default.
• W2079118742 hasRelatedWork W3000207698 @default.
• W2079118742 hasRelatedWork W3010735123 @default.
• W2079118742 hasRelatedWork W3011912378 @default.
• W2079118742 hasRelatedWork W3081807968 @default.
• W2079118742 hasRelatedWork W3087356362 @default.
• W2079118742 hasRelatedWork W3167821594 @default.
• W2079118742 hasRelatedWork W3196913005 @default.
• W2079118742 hasRelatedWork W3038103823 @default.
• W2079118742 isParatext "false" @default.
• W2079118742 isRetracted "false" @default.
• W2079118742 magId "2079118742" @default.
• W2079118742 workType "article" @default.